<DOC>
	<DOCNO>NCT00054028</DOCNO>
	<brief_summary>This phase I/II trial study best dose suramin give together paclitaxel treat woman stage IIIB-IV breast cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Suramin may increase effectiveness paclitaxel make tumor cell sensitive drug .</brief_summary>
	<brief_title>Suramin Paclitaxel Treating Women With Stage IIIB-IV Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose suramin combination paclitaxel ( TXT ) result suramin plasma concentration approach 10-50 uM duration , TXT plasma therapeutically significant level , woman stage IIIB IV breast cancer . ( Phase I ) II . Determine objective response rate patient treat regimen . ( Phase II ) SECONDARY OBJECTIVES : I . Determine pharmacokinetics low-dose suramin patient . ( Phase I ) II . Determine time tumor progression patient treat regimen . ( Phase II ) III . Determine 1-year survival patient treat regimen . ( Phase II ) OUTLINE : This phase I , dose-escalation study suramin follow phase II multicenter study . PHASE I : Patients receive low-dose suramin intravenously ( IV ) 30 minute paclitaxel IV 1 hour weekly . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive adjust dos suramin target dose determine . The suramin target dose define dose least 5 6 patient achieve target plasma concentration 10-50 uM duration paclitaxel level therapeutic . PHASE II : Patients receive paclitaxel combination target dose suramin . PROJECTED ACCRUAL : A total 6-18 patient accrued phase I study within 9 month . A total 28 patient accrue phase II study within 18-24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<criteria>Patients must histologically cytologically confirm stage IIIB IV metastatic breast cancer ( MBC ) Prior chemotherapy : Phase I : patient must receive prior paclitaxel taxanes either adjuvant metastatic setting ; prior chemotherapy , radiation surgery must complete least 21 day study entry ; prior treatment anthracyclines require Phase II : two prior chemotherapy regimens stage IIIB IV MBC ; patient must receive prior paclitaxel taxanes either adjuvant metastatic setting ; prior chemotherapy , radiation surgery must complete least 21 day study entry ; prior treatment anthracyclines require Measurable disease ( phase II ) No know brain metastasis Hormone receptor status : Not specify Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 White blood cell ( WBC ) least 3,000/mm^3 Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Bilirubin great 1.5 mg/dL Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) great 2.5 time upper limit normal Creatinine great 1.5 mg/dL Left ventricular ejection fraction ( LVEF ) least low limit normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attributable compound similar chemical biological composition Cremophor No concurrent uncontrolled illness would preclude study compliance No ongoing active infection No uncontrolled diabetes mellitus No psychiatric illness social situation would preclude study compliance No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No 2 prior chemotherapy regimen malignancy ( phase II ) No concurrent steroid hormone except follow : Steroids prevent hypersensitivity reaction prior paclitaxel administration Hormones nondiseaserelated condition ( e.g. , insulin diabetes ) At least 3 week since prior radiotherapy recover At least 3 week since prior surgery recover No concurrent combination antiretroviral therapy human immunodeficiency virus ( HIV ) positive patient No concurrent investigational agent Concurrent bisphosphonates ( i.e. , pamidronate zoledronate ) allow treatment hypercalcemia palliation skeletal metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>